tions, health care utilization, and costs in 12-month follow-up period were assessed. Complications included microvascular (e.g. diabetic retinopathy), macrovascular (e.g. atherosclerosis), and other diabetic complications. Cox proportional hazards models were used to compare complication rates, adjusting for baseline characteristics. Generalized linear models/two-part models were similarly used for utilizations and costs. RESULTS: The study included 15,139 patients (47.0% female; mean age 52.6 [SDϭ8.1]) receiving DPP4i combinations and 41,602 patients (42.4% female; mean age 51.9 [SDϭ8.3]) receiving SU combinations. At baseline, DPP4i patients had higher rates of medication use than SU patients (MET: 61.7% vs. 40.4%; TZD: 23.0% vs. 11.8%; lipid-lowering: 53.2% vs. 35.4%; number of different medications: 7.2 [SDϭ5.1] vs. 5.3 [SDϭ4.9], respectively; all PϽ0.0001). After adjustment, hazard ratios of complications were significantly lower for patients treated with DPP4i combinations (microvascular complications: 0.872, PϽ0.0001; macrovascular complications: 0.933, Pϭ0.0015; other complications: 0.921, PϽ0.0001). DPP4i patients also had lower adjusted diabetes-related utilization incidence rate ratios (hospitalization: 0.76; ER visits: 0.69; outpatient visits: 0.87; all PϽ0.0001). DPP4i patients incurred higher mean diabetes-related prescription drug costs ($1,629 vs. $476, PϽ0.0001) but lower all-cause medical services costs ($6731 vs. $7251, PϽ0.0001). CONCLUSIONS: Compared to SU combinations, DPP4i combinations are associated with lower rates of diabetic complications and health care utilization. While patients on DPP4i combination incur higher diabetes-related drug costs, they were found to have lower all-cause medical-services costs.
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PDB18 DIRECT MEDICAL COSTS OF DIABETES MELLITUS IN CHINA: ANNUAL COST OF ILLNESS AND LONG-TERM PROJECTIONS USING A VALIDATED DIABETES MODEL

OBJECTIVES:
The prevalence of diabetes in China is rising, and was recently estimated as 9.7% in The China National Diabetes and Metabolic Disorders Study, with a large proportion of patients previously undiagnosed. The costs of treating complications in all patients and managing the disease in diagnosed patients are high. The aim of this study was to estimate the annual cost of illness for all patients and lifetime diabetes costs for diagnosed patients in China. METHODS: A model was developed to estimate the cost of diabetes for 2011. Diabetes complication costs were derived from hospital surveys in Beijing and Chengdu. Diabetes treatment strategies were based on the intensive arm of the UK Prospective Diabetes Study (UKPDS). The annual incidence and prevalence rates for major diabetic complications, including cardiovascular, renal, ocular, foot ulcer, neuropathy and treatment-related events, were derived from international studies of diagnosed patients with baseline disease duration of less than ten years, including the UKPDS. All patients were at risk of incurring complication costs, and only diagnosed patients could incur treatment and management costs. For diagnosed patients lifetime cost projections were made, discounted by 3% annually, using a validated diabetes model. RESULTS: The 2011 cost of diabetes was estimated as CNY 13,326 per diagnosed and CNY 4,727 per undiagnosed patient, with the difference attributable to diabetes treatment and management costs. Based on a total population approaching 1.4 billion and previously reported disease prevalence rates, the national cost of diabetes in 2011 was estimated as CNY 1,214 billion. In diagnosed patients, a lifetime cost of CNY 301,716 per patient was estimated (or CNY 18,253 billion nationally); diabetes complications comprised 53% of total costs. CONCLUSIONS: The costs of diabetes in China are high. Based on a Gross Domestic Product (GDP) of CNY 47,156.4 billion for 2011, appropriate care for every diabetic in China would cost 2.6% of GDP. The objective of the study was to estimate current direct costs associated with diabetes-related complications in Malaysia. METHODS: Most direct costs of diabetes complications were derived from interviews with three key opinion leaders in the field of diabetes in Malaysia. Dialysis costs were sourced from published literature. Mean costs were then estimated calculated for first and subsequent years for each event/complication. All costs are presented in 2011 Malaysian Ringgits (MYR) (converted to US dollars [USD], exchange rate USD 1 to MYR 3.14). RESULTS: Endstage renal disease was associated with the highest annual per patient costs, with mean first year costs for hemodialysis and peritoneal dialysis being MYR23,500 (USD7,070) and MYR36,000 (USD11,465) per year, respectively. Costs of renal transplant were MYR26,000 (USD8,280) in the year of transplant and MYR3,000 (USD955) per year in subsequent years. Other complications associated with high direct costs were amputation and prosthesis (MYR425 and MYR3, 750, respectively [USD135 and USD1, 194, respectively] ), cataract operation (MYR3,221, USD1,026) and myocardial infarction (MYR1,233 [USD393] in year of event and MYR367 [USD117] per year in subsequent years). Additionally, neuropathy was associated with mean costs of MYR900 (USD287) in the first year and MYR675 (USD215) per year thereafter. CONCLUSIONS: Diabetes is associated with a substantial economic burden in Ma-laysia, and the management of diabetes related complications is likely to represent a significant proportion of the overall costs. The cost data reported in this study represents a useful resource for future economic evaluations of diabetes in Malaysia. OBJECTIVES: Indonesia has the fourth highest number of cases of diabetes mellitus in the world. Estimates from 2010 indicated that approximately 7,000,000 people in Indonesia had diabetes. Although diabetes-related complications are associated with a considerable economic burden, there is a paucity of data on the costs of diabetes in Indonesia. The aim of the present study was to estimate the direct costs associated with managing diabetes-related complications from a health care payer perspective in Indonesia. METHODS: Literature review of EMBASE, PubMed, the Cochrane Library and grey literature provided few publications to inform cost estimates. Costs were evaluated based on interviews with local expert physicians and were collected for the first year of treatment and each subsequent year per event/complication. Costs were classified into six main groups: cardiovascular complications, renal complications, acute events, eye-disease, neuropathy and diabetic foot complications, and concomitant medications. Costs were expressed in 2011 Indonesian Rupiah (IDR) with US dollar (USD) conversions (exchange rate USD1 to IRD8,940). RESULTS: Myocardial infarction was the most costly cardiovascular complication with a first year cost of IDR202.7 million (USD22,673), followed by stroke, unstable angina and heart failure. Renal complications were also significant contributors of cost with transplantation estimated to cost approximately IDR192.5 million (USD21,532) in the first year and IDR45 million (USD5,033) in each subsequent year. Hemodialysis cost over IDR89.3 million (USD9,994) annually and peritoneal dialysis cost over IDR57.1 million (USD6,391) each year. The most expensive ocular procedure was cataract surgery (IDR5.1 million [USD573]). Lower limb amputation was the most costly of the diabetic foot complications (IDR21.2 million [USD2,375]). CONCLUSIONS: Estimates of complication costs suggest that the 7 million patients with diabetes represent a substantial economic burden in Indonesia. The data collected in this study represent a valuable resource to investigate the economic impact of diabetes treatments in the Indonesian setting.
PDB19 ESTIMATING THE COSTS OF DIABETES MELLITUS: AN ANALYSIS IN MALAYSIA
PDB20 ESTIMATING THE DIRECT MEDICAL COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS IN INDONESIA
PDB21 DIRECT MEDICAL COSTS OF DIABETES-RELATED COMPLICATIONS IN INDIA
Todorova L 1 , Hnoosh A 2 , Korde G 3 , Shiu ML 4 1 Novo Nordisk International Operations, Zurich, Switzerland, 2 IMS Health Consulting Group, London, UK, 3 IMS Health Consulting Group, Mumbai, India, 4 Novo Nordisk Pharma Operations (BAOS) Sdn. Bhd., Kuala Lumpur, Malaysia OBJECTIVES: Diabetes is associated with a substantial and growing clinical and economic burden in India, accounting for approximately 11% of national health care expenditure in 2010. Moreover, the management of diabetes-related complications is the main contributor to the overall cost of the disease. The objective of the study was to obtain current direct costs for the management of diabetes-related complications in India. METHODS: Direct costs of diabetes-related complications were derived from interviews with three expert diabetologists based in India, with the exception of the costs of renal procedures, which were derived from published, country-specific literature. Mean values based on all experts' estimates were calculated for first and subsequent years for each complication. Costs were classified into 6 groups (management, cardiovascular complications, renal-complications, acute-events, eye-disease and neuropathy/foot ulcers had the highest costs of the diabetic foot complications. CONCLUSIONS: In India, direct costs associated with the management of diabetes-related complications, in particular renal and cardiovascular complications, contribute significantly to the economic burden associated with diabetes. Costs presented in this study will provide useful data for economic evaluations of diabetes interventions in India.
PDB22 THE DIRECT MEDICAL COST FOR DIABETES MELLITUS (DM) RELATED COMPLICATIONS IN CHINA
Zheng Y 1 , Österle A 2 , Liu X 1 , Wu J 1 1 Tianjin University, Tianjin, China, 2 Vienna University of Economics and Business, Vienna, Austria OBJECTIVES: To estimate the direct medical cost for diabetes mellitus (DM) related complications in China. METHODS: Data were obtained from a cross-sectional survey of 20 internists of endocrine and metabolism departments in 20 hospitals from September to November in 2011 in 9 cities of China. 11 internists worked in tier 3 hospitals and 9 worked in tier 2 hospitals. All the internists who are department director or deputy director were asked to give the average costs of complications treatment according to their clinical practice and retrospective medical re-A662 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 -A 6 8 1
